Aarti Drugs Limited has announced a scheduled board meeting to review its quarterly financial performance and consider shareholder returns through potential dividend distribution.

Board Meeting Details

The pharmaceutical company has informed stock exchanges that its Board of Directors will meet on Tuesday, February 3, 2026. The meeting has been convened under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Agenda Items

The board meeting will address two primary matters of significant importance to stakeholders:

• Financial Results Approval: The directors will consider, approve and take on record the audited financial results (both standalone and consolidated) for the quarter and nine months ended December 31, 2025
• Dividend Declaration: The board will deliberate on declaring an interim dividend for FY 2025-26, subject to approval

Trading Window Restrictions

In accordance with regulatory compliance requirements, Aarti Drugs Limited has implemented trading window restrictions. The company's trading window will remain closed until 48 hours after the declaration of the financial results. This closure was previously communicated to exchanges on December 29, 2025.

Regulatory Compliance

The announcement was formally communicated to both major Indian stock exchanges through official correspondence. Company Secretary and Compliance Officer Rushikesh Vivek Deole signed the notification, ensuring adherence to disclosure requirements.

The company has made this information available on its official website at www.aartidrugs.com , ensuring transparent communication with all stakeholders regarding the upcoming board meeting and its agenda items.

Aarti Drugs Limited , a prominent player in the Indian pharmaceutical sector, has reported a robust performance for the second quarter of fiscal year 2026. The company's financial results showcase significant growth across key metrics, highlighting its strong market position and operational efficiency.

Financial Performance

Aarti Drugs reported quarterly revenue of ₹653.00 crores, representing a 9% year-over-year growth. The company's EBITDA increased by 23% to ₹84.00 crores, with margins improving to 12.90%. This performance demonstrates the company's ability to enhance profitability while expanding its revenue base.

Operational Highlights and Strategic Initiatives

The company has made significant strides in enhancing its operational capabilities:

1. Commissioning of Sayakha Amines Plant: Aarti Drugs has commissioned its Sayakha Amines plant, a strategic move to boost self-sufficiency for Metformin production.

2. Tarapur Salicylic Acid Production: The company expects its Tarapur Salicylic Acid production line to reach a monthly capacity of 500 tonnes by Q4FY26, indicating a substantial increase in production capabilities.

3. Growth Strategy: Aarti Drugs is targeting sustained double-digit growth through backward integration and export expansion. The company plans to strengthen its U.S. and EU regulatory approvals to drive high-value API exports and margin expansion over FY27-FY29.

Capital Restructuring

In a move to optimize its capital structure, Aarti Drugs completed a buyback of 6.65 lakh equity shares at ₹900.00 per share in September. This strategic decision resulted in a reduction of the company's paid-up share capital to ₹91.27 crore.

Looking Ahead

As Aarti Drugs continues to demonstrate strong financial growth and operational expansion, investors and industry observers will be keen to see if the company can maintain this momentum in the coming quarters. The pharmaceutical sector remains dynamic, with opportunities for companies that can innovate, operate efficiently, and navigate challenges effectively.

Aarti Drugs' Q2 results and strategic initiatives position it as a company to watch in the Indian pharmaceutical space, reflecting its resilience and growth potential in a competitive market environment.